GW Pharmaceuticals

April 5, 2017

Europe Grants Orphan Drug Status to Epidiolex to Treat Severe Form of Children’s Epilepsy

News

The European Union has granted orphan drug status to the cannabinoid therapy Epidiolex to treat Lennox-Gestaut syndrome (LGS), a treatment-resistant, childhood-onset form of epilepsy. Epidiolex, GW Pharmaceuticals‘ lead cannabinoid (CBD) product candidate, is a proprietary ... Read more

December 7, 2016

GW Pharmaceuticals Presents Positive Results of Cannabidiol Epidiolex at Epilepsy Confab

News

GW Pharmaceuticals recently presented positive results from two Phase 3 clinical trials evaluating its lead cannabidiol therapeutic candidate, Epidiolex, in patients with lennox-gastaut syndrome (LGS) and Dravet syndrome (DS), two treatment-resistant ... Read more